TOMM40 alterations in Alzheimer's disease over a 2-year follow-up period.


Journal Article

We previously reported TOMM40 to be significantly down-regulated in whole blood of Alzheimer's disease (AD) subjects at baseline and after one-year. In this longitudinal follow-up study of TOMM40 expression up to 2 years, we performed 6-monthly assessments for the first year and 2nd year blood sampling on 27 probable AD subjects compared with age- and gender-matched controls. TOMM40 gene expression remained significantly lower in AD patients at all time-points compared to controls, supported by confirmatory RT-PCR results. Our findings of consistently lower TOMM40 expression on longitudinal 2-year sampling support its potential role as a diagnostic blood AD biomarker.

Full Text

Cited Authors

  • Goh, LK; Lim, WS; Teo, S; Vijayaraghavan, A; Chan, M; Tay, L; Ng, TP; Tan, CH; Lee, TS; Chong, MS

Published Date

  • 2015

Published In

Volume / Issue

  • 44 / 1

Start / End Page

  • 57 - 61

PubMed ID

  • 25201778

Pubmed Central ID

  • 25201778

Electronic International Standard Serial Number (EISSN)

  • 1875-8908

Digital Object Identifier (DOI)

  • 10.3233/JAD-141590


  • eng

Conference Location

  • Netherlands